LMAN2L
VIP36-like protein
Also known as: DKFZp564L2423, LMA2L_HUMAN, VIPL
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9H0V9
- Gene
- LMAN2L
- Ensembl
- ENSG00000114988
- Chromosome
- 2
- Canonical length
- 348 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted membrane proteins
OverviewNCBI Gene
This gene encodes a protein belonging to the L-type lectin group of type 1 membrane proteins, which function in the mammalian early secretory pathway. These proteins contain luminal carbohydrate recognition domains, which display homology to leguminous lectins. Unlike other proteins of the group, which cycle in the early secretory pathway and are predominantly associated with post endoplasmic reticulum membranes, the protein encoded by this gene is a non-cycling resident protein of the ER, where it functions as a cargo receptor for glycoproteins. It is proposed to regulate exchange of folded proteins for transport to the Golgi and exchange of misfolded glycoproteins for transport to the ubiquitin-proteasome pathway. [provided by RefSeq, Apr 2016]
Canonical amino-acid sequenceUniProt
348 residues, UniProt reviewed canonical sequence.
>Q9H0V9|LMAN2L
1 MAATLGPLGS WQQWRRCLSA RDGSRMLLLL LLLGSGQGPQ QVGAGQTFEY LKREHSLSKP
61 YQGVGTGSSS LWNLMGNAMV MTQYIRLTPD MQSKQGALWN RVPCFLRDWE LQVHFKIHGQ
121 GKKNLHGDGL AIWYTKDRMQ PGPVFGNMDK FVGLGVFVDT YPNEEKQQER VFPYISAMVN
181 NGSLSYDHER DGRPTELGGC TAIVRNLHYD TFLVIRYVKR HLTIMMDIDG KHEWRDCIEV
241 PGVRLPRGYY FGTSSITGDL SDNHDVISLK LFELTVERTP EEEKLHRDVF LPSVDNMKLP
301 EMTAPLPPLS GLALFLIVFF SLVFSVFAIV IGIILYNKWQ EQSRKRFYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LMAN2L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 21 nTPM
Expression across tissuesHPA
Tissue
- ovary: 21 nTPM
- heart muscle: 18 nTPM
- tongue: 18 nTPM
- liver: 18 nTPM
- kidney: 17 nTPM
- pituitary gland: 17 nTPM
Single-cell type
- myonuclei: 79 nCPM
- choroid plexus epithelial cells: 52 nCPM
- proximal tubule cells: 46 nCPM
- corticotrophs: 36 nCPM
- lactotrophs: 34 nCPM
- thyrotrophs: 33 nCPM
Immune cell
- basophil: 38 nTPM
- MAIT T-cell: 32 nTPM
- eosinophil: 22 nTPM
- plasmacytoid DC: 21 nTPM
- memory B-cell: 20 nTPM
- naive CD4 T-cell: 20 nTPM
Brain region
- hypothalamus: 23 nTPM
- medulla oblongata: 13 nTPM
- pons: 12 nTPM
- midbrain: 12 nTPM
- thalamus: 11 nTPM
- basal ganglia: 11 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about LMAN2L.
Disease | AllUniProt
Conditions LMAN2L is implicated in, by any mechanism.
- Intellectual developmental disorder, autosomal recessive 52 (MRT52) MIM:616887
- Intellectual developmental disorder, autosomal dominant 69 (MRD69) MIM:617863
Disease | GeneticClinVar
3 pathogenic / likely-pathogenic of 84 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Intellectual disability, autosomal recessive 52
- Intellectual developmental disorder, autosomal dominant 69
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.3
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.19
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LMAN2L as an antibody target. Whether an autoantibody or antibody against LMAN2L could matter depends on whether native LMAN2L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LMAN2L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LMAN2L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...